The U.S. Department of Defense has awarded a substantial $876,000 grant to Cedars-Sinai Medical Center to support critical biomarker research for Kairos Pharma’s innovative lung cancer treatment approach. The funding will support research conducted in Dr. Neil Bhowmick’s laboratory, targeting patients with EGFR-driven non-small cell lung cancer who are developing resistance to osimertinib.
The research focuses on identifying potential biomarkers that could help clinicians predict and manage treatment resistance in lung cancer patients. Specifically, the study aims to determine which patients might benefit from early intervention with ENV105, a novel therapeutic candidate developed by Kairos Pharma.
ENV105 represents a promising approach to addressing drug resistance in cancer treatment. The antibody targets CD105, a protein identified as a key driver of resistance mechanisms in various cancer therapies. When standard treatments are administered, CD105 can elevate, potentially leading to treatment resistance and disease relapse.
By targeting CD105, ENV105 seeks to potentially reverse drug resistance and restore the effectiveness of standard cancer therapies. This research could have significant implications for lung cancer patients who currently face limited options when initial treatments become ineffective.
The grant aligns with Kairos Pharma’s strategic goal of improving long-term patient outcomes through targeted therapy and precision monitoring. Currently, ENV105 is being investigated in multiple clinical trials, including a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer.
This research represents an important step in understanding and potentially overcoming treatment resistance in cancer, offering hope for more personalized and effective therapeutic strategies in the future.
This news story relied on a press release distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Kairos Pharma Receives DoD Grant for Lung Cancer Biomarker Research.